Implant-associated infections are among the most serious post-surgical complications of medical device implants, including prosthetic joints (e.g., hip, knee and shoulder) and fracture fixation hardware.[1,2] Infection rates related to orthopedic implants have been reduced to below 5% owing to strict hygienic protocols and intraoperative systemic prophylactic treatment.[3] However, the overall number of such infections has been continuously increasing with growing demands for surgical implantation as a result of population aging and increasing participation in recreational activities.[4] Timely diagnosis of implant-associated infections is a significant challenge, and established infections may not be effectively treated with long-term systemic antibiotic therapy.[2] Therefore, postsurgical infections often require complex additional surgical procedures such as debridement, prosthesis removal and re-implantation. Even systemic antibiotic treatment raises several concerns, such as systemic toxicity, low efficiency and need for hospitalization. Given this context, extended delivery of antimicrobial agents at the site of implantation is highly desirable to offer high local antibiotic concentration without systemic toxicity and thereby prevent postoperative, implant-associated infections.